EISAI CO
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- Public
- Established
- 1941-12-06
- Employees
- 11K
- Market Cap
- $12B
- Website
- http://www.eisai.co.jp
Pharmacokinetic Study of Perampanel in Chinese Healthy Subjects
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 44
- Registration Number
- NCT03424564
- Locations
- π¨π³
Eisai Trial Site, Beijing, Beijing, China
A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma
- First Posted Date
- 2018-02-01
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03418922
- Locations
- π―π΅
Eisai Trial Site 3, Kawasaki, Kanagawa, Japan
π―π΅Eisai Trial Site 1, Kashiwa, Chiba, Japan
π―π΅Eisai Trial Site 6, Iizuka, Fukuoka, Japan
Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2082 in Healthy Male Subjects
- First Posted Date
- 2018-01-18
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 118
- Registration Number
- NCT03402178
- Locations
- π―π΅
Eisai Trial Site, Sumida-ku, Tokyo, Japan
Bioequivalence Study Between a 4-mg Dose of Fine Granules of Perampanel and a 4-mg Tablet of Perampanel in Healthy Japanese Subjects
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2018-10-29
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT03399734
- Locations
- π―π΅
Eisai Trial Site, Toshima-ku, Tokyo, Japan
Study of E7389 Liposomal Formulation in Participants With Solid Tumor
Phase 1
Active, not recruiting
- Conditions
- Solid Tumor
- Interventions
- Drug: E7389-LF
- First Posted Date
- 2017-07-05
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 140
- Registration Number
- NCT03207672
- Locations
- π―π΅
Eisai Trial Site 5, Sapporo, Hokkaido, Japan
π―π΅Eisai Trial Site 1, Chuo-ku, Tokyo, Japan
π―π΅Eisai Trial Site 10, Hidaka, Saitama, Japan
Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study)
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2021-08-05
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 91
- Registration Number
- NCT03201900
- Locations
- π―π΅
Eisai Trial Site #29, Fukuoka, Japan
π―π΅Eisai Trial Site #30, Miyagi, Japan
π―π΅Eisai Trial Site #10, Kyoto, Japan
Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures
Completed
- Conditions
- Partial Seizures (With or Without Secondary Generalized Seizures)Primary Generalized Tonic-clonic Seizures
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 519
- Registration Number
- NCT03059381
Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures
Completed
- Conditions
- Partial Seizures (With or Without Secondary Generalized Seizures)Primary Generalized Tonic-clonic Seizures
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 3809
- Registration Number
- NCT03059329
A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas
- First Posted Date
- 2017-02-20
- Last Posted Date
- 2020-04-06
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 256
- Registration Number
- NCT03058406
Study to Evaluate the Safety and Tolerability of a Once Daily Dose of 50 mg E2609 in Healthy Japanese Subjects
- First Posted Date
- 2017-02-16
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT03055962
- Locations
- π―π΅
Eisai Trial Site, Fukuoka, Japan